Equities research analysts expect Stryker Co. (NYSE:SYK) to post earnings per share (EPS) of $1.90 for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Stryker’s earnings. The lowest EPS estimate is $1.89 and the highest is $1.92. Stryker reported earnings per share of $1.69 in the same quarter last year, which suggests a positive year over year growth rate of 12.4%. The firm is expected to announce its next earnings results on Thursday, October 24th.
On average, analysts expect that Stryker will report full-year earnings of $8.21 per share for the current financial year, with EPS estimates ranging from $8.15 to $8.24. For the next year, analysts expect that the firm will post earnings of $9.01 per share, with EPS estimates ranging from $8.91 to $9.07. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Stryker.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 25th. The medical technology company reported $1.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.05. The business had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.60 billion. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.76 EPS.
Stryker stock traded up $0.49 during mid-day trading on Wednesday, reaching $217.49. 13,085 shares of the company traded hands, compared to its average volume of 1,081,618. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.07 and a quick ratio of 1.26. The firm’s 50 day moving average price is $210.77 and its 200 day moving average price is $194.99. The firm has a market capitalization of $80.54 billion, a price-to-earnings ratio of 29.74, a P/E/G ratio of 2.61 and a beta of 0.85. Stryker has a 52-week low of $144.75 and a 52-week high of $222.59.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 0.96%. The ex-dividend date of this dividend is Friday, September 27th. Stryker’s dividend payout ratio (DPR) is 28.45%.
In related news, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $197.68, for a total transaction of $922,374.88. Following the sale, the insider now directly owns 155,347 shares of the company’s stock, valued at approximately $30,708,994.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Srikant M. Datar sold 350 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $215.00, for a total transaction of $75,250.00. Following the sale, the director now directly owns 6,844 shares in the company, valued at $1,471,460. The disclosure for this sale can be found here. Insiders have sold a total of 15,781 shares of company stock worth $3,249,739 over the last three months. 7.20% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd lifted its stake in Stryker by 104.2% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 1,272 shares of the medical technology company’s stock valued at $261,000 after acquiring an additional 649 shares during the period. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Stryker by 85.4% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 5,009 shares of the medical technology company’s stock valued at $1,030,000 after acquiring an additional 2,307 shares during the period. UBS Group AG lifted its stake in Stryker by 11.6% during the 2nd quarter. UBS Group AG now owns 625,722 shares of the medical technology company’s stock valued at $128,635,000 after acquiring an additional 64,981 shares during the period. WealthStone Inc. bought a new position in Stryker during the 2nd quarter valued at about $107,000. Finally, Columbia Asset Management lifted its stake in Stryker by 12.8% during the 2nd quarter. Columbia Asset Management now owns 26,513 shares of the medical technology company’s stock valued at $5,451,000 after acquiring an additional 3,008 shares during the period. 74.14% of the stock is currently owned by institutional investors.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.